Veradermics, Absci and Cosmo have seen their share prices explode after announcing promising early data on treatments for pattern baldness. The companies, which went public or rose sharply in 2026, are being compared with the recent surge in GLP-1 obesity drugs that lifted Eli Lilly and Novo Nordisk to multi-trillion-dollar valuations.
Why the market is buzzing
Pattern hair loss affects an estimated 50 million men and 30 million women in the United States alone, yet the last drug approval for the condition dates back to the late 1990s. Existing options, over-the-counter minoxidil and prescription finasteride, can cause side effects such as heart palpitations or reduced libido. Because the condition is largely cosmetic, patients typically pay out-of-pocket, creating a cash-pay market that investors see as a goldmine.
Potential market size
Analysts point to the willingness of consumers to spend on aesthetic improvements, a trend that drove the GLP-1 weight-loss boom. Jefferies estimates that a successful male-hair-loss therapy could generate up to $3 billion in global sales, provided a capable commercial partner is secured. The same firm expects the share price of Cosmo to double within the next year.
Pipeline developments
Cosmo's lead candidate, clascoterone, is a topical formulation that blocks a hormone directly at the hair follicle. The company plans to file a new drug application with the US Food and Drug Administration in the first quarter of 2027. Veradermics reported positive results for an oral minoxidil tablet in men and promising mid-stage data for women, which could become the first approved pill for female-pattern hair loss.
"People will fly all the way to Turkey to have some hair moved around on their head," said Needham analyst Gil Blum, who rates Absci a buy. "Can you imagine if you could do that without getting a hair transplant?"
Absci is developing an AI-designed injectable, ABS-201, with interim data expected later this year. Geoff Hsu, portfolio manager at OrbiMed, noted that both obesity and hair loss represent large consumer markets, offering significant revenue potential if safe, effective drugs emerge.
Risks and outlook
Drug development remains high risk; many candidates fail to reach the market, and unlike GLP-1 drugs, hair-loss treatments are unlikely to receive insurance coverage. Nevertheless, analysts argue that the cash-pay nature of the market could support multiple products, as patients often combine prescription and over-the-counter options.
"This space definitely can accommodate multiple drugs," said Jefferies analyst Roger Song, who holds the Street's highest price target on Veradermics. "Many hair loss patients tend to use multiple drugs, either prescription or over-the-counter, as long as they can afford it, because it's a cash-pay market."
With data expected from several candidates over the next 12 months, the sector could see further share price volatility. Investors who view the space as a "zero or hero" story are positioning themselves early, hoping to capture the upside of what could become a multi-billion-dollar market.